“`html
Semi-Annual Injection Shows Promise in Treating Hypertension
Table of Contents
- Semi-Annual Injection Shows Promise in Treating Hypertension
By Amelia Hernandez | WASHINGTON D.C. – 2025/06/20 21:54:45
A new semi-annual injection treatment offers a potential alternative to daily pills for millions of individuals with hypertension, promising stable blood pressure management for extended periods.
An injection every 6 months to lower the tension?
A novel semi-annual injection could revolutionize hypertension treatment, offering a reprieve from daily medication. This innovative approach aims to maintain consistent blood pressure levels for several months following a single subcutaneous injection.
long -lasting treatment that acts on the liver
The treatment leverages interfering RNA (RNAi) technology, targeting the liver to inhibit the production of angiotensinogen, a protein crucial in blood pressure regulation.By blocking this protein,blood vessels remain relaxed,leading to a sustained reduction in blood pressure.
The first results are notable: a clear and continuous drop in systolic tension, sometimes greater than 15 mmHg.
Visible effects on blood pressure
Early results indicate a significant and consistent decrease in systolic blood pressure, often exceeding 15 mmHg. This effect persists for six months post-injection, eliminating the need for daily medication. This could provide significant relief for individuals with severe or treatment-resistant hypertension.
why it’s a little revolution
Non-adherence to hypertension medication is a widespread issue, with approximately 50% of patients discontinuing treatment within a year, often due to the burden of daily pills and associated side effects. This new injectable format has the potential to transform hypertension management by mitigating the risks associated with non-compliance, removing the need for daily medication routines.
Less risks of side effects?
Initial data suggests favorable tolerability, with minimal reported side effects. The primary concern is the potential for excessively low blood pressure,which can be managed with existing emergency interventions. However, further research is needed to confirm this safety profile over extended durations.
Who is this treatment for?
Currently, this treatment is intended for patients who do not respond adequately to conventional medications. However, it may eventually be suitable for a broader population, including adults seeking cardiovascular prevention, elderly individuals, and patients prone to forgetting their medication.
Soon available in pharmacy?
While the drug is not yet commercially available, advanced clinical trials are ongoing. If the results remain promising, regulatory authorities may approve its market release by 2026. Additional injectable treatments with similar long-term efficacy and convenience are also under development.
What to remember
- A single injection every six months can effectively lower blood pressure.
- The treatment directly targets a key protein produced by the liver.
- it has the potential to improve treatment adherence and reduce cardiovascular complications.
- Ongoing trials are evaluating its long-term effectiveness.
Frequently Asked Questions About the New hypertension Injection
- how often is the injection administered?
- The injection is administered once every six months.
- How does the injection work?
- The injection uses RNAi technology to target and block the production of angiotensinogen in the liver, a protein that raises blood pressure.
- What are the potential side effects?
- The main potential side effect is excessively low blood pressure, which can be managed with existing treatments.
- When will the injection be available?
- If clinical trials continue to show positive results, the injection could be available by 2026.
- Who is the injection suitable for?
- Initially, the injection is intended for patients who do not respond well to conventional hypertension medications, but it may eventually be used for a wider range of patients.
